Baseline demographics and disease characteristics of rituximab-treated and placebo-treated patients with RA
| Rituximab STY (N=104) | Rituximab STN (N=1356) | Placebo STY (N=57) | Placebo STN (N=721) | |
|---|---|---|---|---|
| Female, % | 71.2 | 82.5 | 77.2 | 80.7 |
| Age, mean (SD), years | 59.3 (8.9) | 49.8 (12.8) | 60.7 (8.3) | 50.0 (12.4) |
| Duration of RA, mean (SD), years | 7.8 (8.4) | 6.8 (8.0) | 8.4 (7.6) | 6.8 (7.6) |
| No. of previous DMARDs (excluding MTX), mean (SD) | 2.2 (2.4) | 1.8 (2.0) | 2.3 (2.3) | 1.8 (2.0) |
| No. of previous biologics, mean (SD) | 0.7 (1.0) | 0.4 (0.8) | 0.7 (1.0) | 0.5 (0.9) |
| Use of concomitant oral steroids, % | 48.1 | 53.2 | 49.1 | 56.2 |
| RF and/or anti-CCP antibody positive, % | 81.8 | 88.7 | 80.7 | 90.1 |
| DAS28-ESR, mean (SD) | 6.8 (1.0) | 6.8 (1.0) | 6.2 (1.5) | 6.3 (1.4) |
Anti-CCP, anti-cyclic citrullinated peptide; DAS28-ESR, Disease Activity Score 28 using erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; STN, no statins; STY, statins.